 phase chronic daili dose oral etoposid combin cisplatin patient advanc cancer dose escal studi daili oral etoposid cisplatin patient advanc cancer dose etoposid day cisplatin IV day total cours myelosuppress major dose-limit toxic maximum toler dose oral etoposid day IV cisplatin day dose etoposid day cisplatin day cours grade leukopenia day grade thrombocytopenia dose level nausea vomit patient dose level mild antiemet alopecia signific mucos grade patient toxic partial respons month patient cervic patient small cell lung patient squamou cell lung cancer patient platin analogue-contain regimen recommend dose phase II studi schedul oral etoposid day IV cisplatin day combin regimen schedul effect patient etoposide-sensit malign